Clinical Trial

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Name: A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy — clinical trial record (NCT07564401)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-23

Trial Details

NCT Number	NCT07564401
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Enrollment	80 participants
Start Date	2026-06-16
Primary Completion	2031-03-03 (estimated)
Study Completion	2031-03-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-23